IJO International Journal of Oncology 1019-6439 1791-2423 D.A. Spandidos 10.3892/ijo.2018.4618 ijo-54-01-0152 Articles Novel drug candidates for treating esophageal carcinoma: A study on differentially expressed genes, using connectivity mapping and molecular docking ChenYu-Ting XieJia-Yi SunQi MoWei-Jia Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China Correspondence to: Dr Wei-Jia Mo, Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi 530021, P.R. China, E-mail: gxmumoweijia@163.com 01 2019 02 11 2018 54 1 152 166 08 08 2018 23 10 2018 Copyright: © Chen et al. 2019 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Patients with esophageal carcinoma (ESCA) have a poor prognosis and high mortality rate. Although standard therapies have had effect, there is an urgent requirement to develop novel options, as increasing drug tolerance has been identified in clinical practice. In the present study, differentially expressed genes (DEGs) of ESCA were identified in The Cancer Genome Atlas and Genotype-Tissue Expression databases. Functional and protein-protein interaction (PPI) analyses were performed. The Connectivity Map (CMAP) was selected to predict drugs for the treatment of ESCA, and their target genes were acquired from the Search Tool for Interactions of Chemicals (STITCH) by uploading the Simplified Molecular-Input Line-Entry System structure. Additionally, significant target genes and ESCA-associated hub genes were extracted using another PPI analysis, and the corresponding drugs were added to construct a network. Furthermore, the binding affinity between predicted drug candidates and ESCA-associated hub genes was calculated using molecular docking. Finally, 827 DEGs (|log2 fold-change|≥2; q-value <0.05), which are principally involved in protein digestion and absorption (P<0.005), the plasminogen-activating cascade (P<0.01), as well as the ‘biological regulation’ of the Biological Process, ‘membrane’ of the Cellular Component and ‘protein binding’ of the Molecular Function categories, were obtained. Additionally, 11 hub genes were obtained from the PPI network (all degrees ≥30). Furthermore, the 15 first screen drugs were extracted from CMAP (score <−0.85) and the 9 second screen drugs with 70 target genes were extracted from STITCH. Furthermore, another PPI analysis extracted 51 genes, and apigenin, baclofen, Prestwick-685, menadione, butyl hydroxybenzoate, gliclazide and valproate were selected as drug candidates for ESCA. Those molecular docking results with a docking score of >5.52 indicated the significance of apigenin, Prestwick-685 and menadione. The results of the present study may lead to novel drug candidates for ESCA, among which Prestwick-685 and menadione were identified to be significant new drug candidates.

 esophageal carcinoma drug candidates differentially expressed genes target genes functional analysis Connectivity Map molecular docking Introduction

Esophageal carcinoma (ESCA) is one of the most common types of cancer in the digestive system which primarily includes esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (1). According to recent statistics, estimated new cases of and mortality from ESCA account for a large proportion of all cancer in the USA (2). ESCA also ranks in the top ten of cancer incidence and mortality rate worldwide, which is associated with genetic and environmental factors (3). In addition, patients with ESCA have a poor prognosis and high mortality rate that may be associated with glucose-regulated protein 78 (4,5).

At present, several methods are practiced in clinical treatment for ESCA (6). Surgical resection is commonly used to remove cancerous tissue and leads to an improved survival rate. Neoadjuvant chemotherapy (without radiation therapy) provides an improved survival benefit compared with surgery alone (7), but the effects on local control are unclear. Tri-modality treatment (concomitant chemotherapy and radiation therapy followed by surgery) also has a marked effect compared with surgery alone (5). Additionally, several chemotherapy target agents for ESCA have been reported, including fluoropyrimidines [5-fluorouracil (5-FU) and capecitabine], platinum agents (cisplatin and oxaliplatin), taxanes (paclitaxel and docetaxel), irinotecan, mitomycin-C, anthracyclines, methotrexate, vinorelbine and gemcitabine. The combination of two or more drugs has a more marked reaction, as it has been reported to increase the efficacy of chemoradiotherapy in patients with ESCA (8-10). However, intolerance of fluoropyrimidine-based, platinum-based and taxane-based chemotherapy has also been identified in patients, and immune checkpoint blockade therapy remains under investigation (11). Therefore, further research is required for more effective therapeutic methods.

Gene-associated therapy for cancers has become a research focus in recent years (12-16). With regard to ESCA, it was identified that the aberrant transcription and translation of genes affect the synthesis of associated proteins, which has an effect on the corresponding physiological processes, and consequently influences the diagnosis and prognosis of ESCA (17-19). It was also identified that the chemotherapeutic mechanism of ESCA was associated with upregulation and downregulation of genes or DNA repair genes (20,21). In addition, gene levels and certain signaling pathways were identified to be associated with chemotherapy resistance (22,23). For example, it was reported that the expression of myeloid cell leukemia 1 in ESCA cancerous tissue with cisplatin resistance increased in comparison with that in normal tissue (24). Let-7 was also identified to serve a potentially positive function in patients with 5-FU resistance (25), which indicates that the drugs targeted in these pathways or genes are potential candidates for improved treatment. Generally, differentially expressed genes (DEGs) and signaling pathways may be the fundamental reason for the development of ESCA. Thus, research into the biological significance of target genes and their corresponding signaling pathways is required for gene-associated chemotherapy.

However, specific drugs mapped to the target genes and their associated pathways remain unknown. Thus, the aim of the present study was to predict novel drug candidates of ESCA using bioinformatics analysis, which was principally based on the Connectivity Map (CMAP), a database that contains 1,309 Food and Drug Administration-approved small molecules and 7,000 gene expression profiles, and has been widely used to reveal the mechanism of drugs (26). Furthermore, molecular virtual docking was used in the search for matching predicted potential drugs and screened proteins. To a certain extent, the present study may provide a new point of reference for chemotherapy for ESCA, with regard to its molecular biology and the methodology.

 Materials and methods Acquisition of DEGs in ESCA

To acquire the information of gene expression levels in ESCA, the gene expression data of ESCA were downloaded from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) (27), and the edition of TCGA dataset on ESCA was updated on October 13, 2017. The gene expression data of ESCA were normalized into the transcripts per million reads format. The differential expression analysis was further performed on the basis of the normalized data and analysis of variance (ANOVA), which was used for tumor vs. paired normal samples. For the differential analysis methods of ANOVA, genes with |log2 fold-change (FC)|≥2 and q-value <0.05 were considered to be DEGs.

 Analysis of DEGs associated with ESCA Functional analysis of differentially expressed genes

WEB-based GEne SeT AnaLysis Toolkit (Webgestalt; www.webgestalt.org) was used to explain the function of extracted DEGs with an enrichment method of over-representation (enrichment) analysis. Gene Ontology (GO) enrichment analysis was performed to classify the genes into their Biological Process (BP), Cellular Component (CC) and Molecular Function (MF) categories. The Kyoto Encyclopedia of Genes and Genomes (KEGG) (www.kegg.jp) and Protein Annotation Through Evolutionary Relationships (PANTHER) (www.pantherdb.org) analyses were performed to determine the pathways in which the DEGs were significantly involved (28-30).

 Excavation of hub genes of ESCA

For further understanding of genes that may have a significant effect on ESCA, the protein-protein interaction (PPI) network was then drafted via Search Tool for the Retrieval of Interacting Genes (STRING; string-db.org). The interaction between two nodes, which represent two genes, was confirmed using Textmining, Experiments, Databases, Co-expression, Neighborhood, Gene Fusion and Co-occurrence. Degrees of edges were calculated using Cytoscape (29,31-34). Finally, the genes with a degree of ≥30 were selected to be hub genes of ESCA, which were considered to be potential bioactive factors for ESCA and were further involved in the subsequent research.

 Prediction of ESCA-associated drugs and extraction of relevant target genes Drug prediction of ESCA based on CMAP

CMAP (portals. broadinstitute.org/cmap) (26,28) was selected to predict the potential drug molecules for ESCA. Following ID conversion via Affymetrix (www.affymetrix.com/analysis/index.affx), the upregulated and downregulated DEGs were uploaded to CMAP for online analysis. Detailed results from CMAP were downloaded, and the first screening drugs were further acquired following filtering for a score of <−0.85.

 Extraction of target genes for the first screening drugs

To further screen out more significant drug molecules and prepare for the following investigation of potential drug-associated mechanisms in ESCA, the Search Tool for Interactions of Chemicals (STITCH, stitch.embl.de), a protein-compound interactions database that contains 390,000 compounds and 3.6 million proteins, was used in which the Canonical Simplified Molecular-Input Line-Entry System (SMILES) structure of drugs downloaded from PubChem (pubchem.ncbi.nlm.nih. gov) were uploaded in order to search for target genes. In this way, the second screening drugs were extracted when the drugs without STITCH-predicted results were phased out, and their corresponding target genes were obtained. Additionally, intersection between predicted target genes and the extracted DEGs of ESCA was calculated using FunRich (35) for a preliminary understanding of their associations.

 Interaction analysis of drug candidates-target genes-ESCA- associated hub genes

To investigate the associations between the predicted drugs and hub genes of ESCA, the target genes of drugs and hub genes of ESCA were analyzed. First, another PPI network was constructed to analyze the interactions between the two sources of genes aforementioned. Connected nodes, confirmed by experiments and databases, were identified and were considered to be associated genes. The unconnected nodes were not included in the following investigation and their corresponding drugs were eliminated. Up to this point, all the extant drugs were considered to be drug candidates of ESCA in the present study. Furthermore, genes confirmed by PPI were then used for constructing the network of drug candidates-target genes-ESCA-associated hub genes. Further analysis of the selected genes was performed using the same methods as for the aforementioned functional analysis of DEGs of ESCA.

 Molecular docking between predicted drug candidates and hub genes

To further investigate the underlying associations between drugs and hub genes in the drug candidates-target genes-ESCA-associated hub genes network, molecular docking was performed using systemsDock (systemsdock.unit.oist. jp/iddp/home/index), which is a web server for network pharmacology-based prediction and analysis (36,37). Selected by the second PPI analysis, protein names of the ESCA-associated hub genes in the network were added and specified, then the SMILES structures of drug candidates involved in the network were also uploaded. A protein and a drug were tested each time. The binding affinity between each hub gene and drug groups was predicted by docking scores.

 Results DEGs of ESCA and functional analysis

A total of 827 DEGs were downloaded from TCGA and GTEx databases with the criteria of |log2FC|≥2 and q-value <0.05 in ANOVA, which includes 375 upregulated genes and 452 downregulated genes (Fig. 1). The following KEGG analysis showed that DEGs were significantly involved in 10 pathways (P<0.005), particularly in protein digestion and absorption, extracellular matrix-receptor interaction and complement, and coagulation cascades (Table I). A PANTHER analysis indicated that DEGs were significantly involved in five pathways (P<0.05), among which the plasminogen-activating cascade, blood coagulation and integrin signaling pathway were particularly significant (P<0.01; Table II). Classified by GO enrichment analysis, the DEGs were primarily involved in the ‘biological regulation’, ‘metabolic process’ and ‘response to stimulus’ BP categories, and the ‘membrane’ and ‘vesicle’ CC categories. They also were involved in the ‘nucleus’ CC category, and in the ‘protein binding’, ‘ion binding’ and ‘hydrolase activity’ MF categories (Fig. 2). Furthermore, 11 genes, including elastin (ELN), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), intercellular adhesion molecule 1 (ICAM1), topoisomerase 2A (TOP2A), interleukin 1B (IL1B), collagen type I α1 (COL1A1), IL8, matrix metalloproteinase 9 (MMP9), secreted phosphoprotein 1 (SPP1), signal transducer and activator of transcription 1 (STAT1) and CXC chemokine ligand 10 (CXCL10), were finally determined to be hub genes following calculation of the edges based on PPI network analysis (all degrees ≥30) (Fig. 3).

 ESCA-associated drugs and relevant target genes

Upregulated and downregulated genes from the TCGA and GTEx databases were uploaded to CMAP, then scores of the predicted ESCA-associated drugs were obtained from the detailed results. Drugs that had a score of <−0.85 were extracted as the first screening drugs for further research, including verteporfin, apigenin, cefixime, Prestwick-685, menadione, baclofen, dequalinium chloride, butyl hydroxybenzoate, naloxone, paroxetine, acetazolamide, gliclazide, valproic acid and metacycline (Table III). Furthermore, Prestwick-685 was categorized as clofazimine by PubChem, whereas dequalinium chloride and butyl hydroxybenzoate were also named dequalinium and butylparaben, respectively. On the basis of STITCH, 70 target genes of 9 second screening drugs were acquired (Fig. 4). In addition, as Fig. 5 presents, only four gene intersections were identified in DEGs of ESCA and target genes of the 9 second screening drugs, which was a preliminary indication that no significant difference in expression of the drug-associated target genes in ESCA was identified.

 Network of drug candidates-target genes-ESCA-associated hub genes Gene association analysis

A total of 70 target genes of drugs and 11 hub genes were united for further analysis. Interactions of the relevant genes were identified in the second PPI network. According to Fig. 6 (with the green circles representing target genes of predicted drugs and yellow circles representing the hub genes of ESCA), 51 genes were considered to be connected and met the criteria of having been confirmed by other experiments and databases. Acetazolamide and dequalinium were eliminated because their target genes were considered meaningless through PPI analysis, thus the other 7 drugs which were relevant to the aforementioned 51 genes were consequently considered as drug candidates of ESCA. As indicated in Fig. 7, associations among the 7 predicted drug candidates-target genes-ESCA-associated hub genes were revealed via network construction, in which the red oblongs represent drug candidates, yellow circles represent 44/51 selected genes (which were also target genes of drug candidates) and blue polygons represent the other 7 genes also belonging to ESCA-associated hub genes.

 Functional analysis of genes

The 51 selected genes were identified to participate principally in 10 pathways, including drug metabolism (cytochrome P450), colorectal cancer and the estrogen signaling pathway (Table I), on the basis of KEGG analysis (P<0.001), as well as 9 pathways on the basis of PANTHER analysis (P<0.05), which, significantly, included the cholecystokinin receptor (CCKR) signaling map and apoptosis signaling pathway (P<0.01; Table II). GO annotation analysis indicated that the results of BP, CC, and MF classification were almost the same as the results of the previous analysis for DEGs of ESCA (Fig. 8). At this point, although 66/70 drug-associated target genes were not differentially expressed in ESCA, they may be regulated by several drugs in order to affect the pathways, including arachidonic acid metabolism, drug metabolism (cytochrome P450) or CCKR signaling map, as well as BP, CC or MF, particularly when regulated by the drug candidates that affect the group of 51 connected genes. Once the drug candidate-associated genes were directly associated with those ESCA hub genes, we hypothesized that they would participate in some way in ESCA pathogenesis. In such a situation, according to the results of the present study, the predicted drugs could associate with ESCA.

 Molecular docking between drug candidates and hub genes

Docking results are presented in Table IV, among which SPP1 and CXCL10 were eliminated because of unspecified protein structures. The binding affinity between the predicted drug candidates and hub genes was evaluated by the docking scores. The score reported by the docking approach in systemsDock is a negative logarithm of experimental dissociation/inhibition constant value (pKd/pKi), usually ranging between 0 and 10 (i.e., from weak to strong binding), allowing a straightforward indication of binding strength. According to Table IV, which lists strength by a decreasing docking score, the molecular docking pairs with a docking score of >5.52 were attributed to drugs including apigenin, Prestwick-685 and menadione, which overall had the top three scores in the CMAP results. The significant results were plotted by respectively selecting the top three proteins for apigenin, Prestwick-685 or menadione (Figs. 9 and 10). A flow chart of the methodology used in the present study is summarized in Fig. 11.

 Discussion

In the present study, 827 DEGs of ESCA were identified, including 375 upregulated genes and 452 downregulated genes, of which the functions were analyzed. On the basis of the PPI network, 11 hub genes were extracted. To acquire potential drugs for ESCA chemotherapy, the DEGs were uploaded to CMAP and 15 drugs were selected by scores. Furthermore, 9/15 drugs were identified to target 70 genes in total. However, only four gene intersections were identified in DEGs of ESCA and 70 target genes. Acetazolamide and dequalinium were also eliminated by another PPI analysis. As a result, apigenin, baclofen, Prestwick-685, menadione, butyl hydroxybenzoate, gliclazide and valproate were considered as the potential drug candidates, and the network of 7 predicted drug candidates-target genes-ESCA-associated hub genes was constructed. Furthermore, apigenin, Prestwick-685 and menadione were considered significant drug candidates by performing molecular docking.

Thus, considering the research design, three steps were taken to obtain the drug candidates for ESCA. First, full use was made of the CMAP, and the first 15 screening drugs were extracted by scores of <−0.85. CMAP is an online database that provides an approach to identifying the connections between small molecules, genes and diseases. It was created by the CMAP team at the Broad Institute and the resource is publicly available (portals.broadinstitute.org/cmap) (26). In CMAP, drug signatures are ordered lists of genes that are stored following the profiling of 564 drug-treated instances and identified by a computer program. Therefore, the CMAP can significantly increase the rate of drug discovery and identify novel uses for existing drugs. For example, Wang et al (38) investigated candidate drugs for hepatocellular carcinoma in the CMAP by analyzing associated subpathways. The CMAP also assisted with the identification of similar signatures of atypical meningiomas and provision of novel treatment methods (39). Additionally, Liu et al (40) used CMAP to identify some potential compounds for treating patients with B-cell chronic lymphocytic leukemia (B-CLL) on the basis of altered pathways in B-CLL. Similarly, in the present study, when 375 upregulated genes and 452 downregulated genes of ESCA were uploaded as a probe set to interrogate the CMAP, this dataset was matched with the drugs identified using a Kolmogorov-Smirnov statistical test. The drugs were sorted by their connectivity scores, which was the combination of the up score and down score. The criterion of a score of <−0.85 was also used to combine a high negative up score and a high positive down score, indicating that the corresponding perturbagen repressed the expression of the probe sets in the up genes list, whereas it induced the expression of the probe sets in the down genes list. Secondly, 6 drugs were eliminated when the standard of STITCH was uniformly adapted. Thirdly, a new PPI analysis was used to establish an association between target genes predicted by the second screening drugs and DEGs of ESCA previously obtained from TCGA and GTEx databases, of which the indicators were artificially set with ‘experiments’ and ‘database’ for a higher reliability. Therefore, those drugs corresponding to the certified associated genes were finally retained as potential drug candidates for ESCA.

The retrieval of relevant literature on drug candidates was required to further understand their research status and clinical application, as well as support the prediction. Among the 7 predicted drugs, apigenin is a natural product that is present in a number of plants. It was confirmed to have an anticancer effect on different types of cancer (41-45). Apigenin was once reported to induce apoptosis in ESCA cells through destruction of the membrane structure (46). As Yan et al (47) summarized, apigenin may be an adjuvant chemotherapeutic agent for cancer therapy by modulating the phosphoinositide 3-kinase/protein kinase B, mitogen-activated protein kinase/extracellular-signal-regulated kinase, Janus kinase/signal transducer and activator of transcription, nuclear factor-κB (NF-κB), and Wnt/β-catenin signaling pathways. In addition, it was also reported that apigenin may have a further function in cancer chemoprevention via the induction of apoptosis and autophagy (48).

Baclofen is commonly used for treating spastic movement disease (49,50). However, baclofen may help to inhibit hiccups following the insertion of a stent for ESCC, according to a case report (51), and it was suggested that it may be a useful adjuvant analgesic for decreasing cancer pain (52). Whether baclofen has any anticancer effects or not remains unknown owing to a lack of relevant research. Prestwick-685, also named clofazimine in PubChem, was identified to be associated with breast cancer (53) and lung cancer (54). Recently, Durusu et al (54) provided novel evidence for the anticancer effect of clofazimine, which implies that clofazimine also requires further investigation regarding cancer treatment. Compared with clofazimine, it appears that menadione, which is also known as vitamin K3, has attracted more attention from the perspective of cancer treatment. Menadione has been identified to exhibit significant therapeutic benefits in the treatment of gastric cancer (55), prostate cancer (56), oral cancer (57) and breast cancer (58). Furthermore, the latest research indicated that menadione may increase anticancer activity by combining ROS-generating agents (59), but how it works in ESCA treatment requires further investigation. Butyl hydroxybenzoate, also called butylparaben, is often used as a flavoring additive in food. However, it is reported to participate in a non-genomic mechanism of activation of G-protein-coupled receptor 30 in cancerous and non-cancerous breast cell lines through activation of the extracellular-signal-regulated kinase 1/2 pathway; further research into the carcinogenic action is required (60). Gliclazide is generally used for treating diabetes (61,62), but its anticancer effect has seldom been explored (63,64). Lastly, valproate has proved to be a potent tool in treating cancer via enhancing doxorubicin cytotoxicity and the efficacy of vinorelbine-cisplatin-based chemoradiation, according to recent studies (65-68). In summary, on the basis of the bioinformatics prediction of the present study and aforementioned studies, apigenin, menadione and valproate are hypothesized to have an increased possibility of becoming the chemotherapeutics for ESCA.

Although a number of the predicted drug candidates for ESCA have not exhibited specific anticancer effects previously, drug repurposing was investigated via efficient bioinformatics analysis and a structure exploration, which means that the excavation of novel drug candidates in the present study was primarily based on the drug repurposing. In particular, the three-step filtering of drug candidates for ESCA executed the drug repurposing simultaneously. In the present study, ESCA was characterized by its DEGs, and the potential effects of drugs were characterized by their target genes. To the extent of searching drugs, the application of extracted DEGs was primarily utilized for screening drugs via CMAP and posteriorly established linkages with drug-associated target genes, which consequently made a connection between ESCA and drugs. In line with this process, the two-time functional analysis of two gene groups, of which one group contains the 827 extracted DEGs of ESCA and the other group contained 51 genes that displayed in the drug candidates-target genes-ESCA-associated hub genes network, explained the underlying pathogenesis of ESCA and predicted the potential influence of drugs. Results of pathway analysis coincided with the arachidonic acid metabolism and drug metabolism (cytochrome P450), on the basis of KEGG analysis, as well as with the CCKR signaling map, on the basis of PANTHER analysis. According to GO analysis, the similar results indicated that, among the drug-associated target genes, 66 unremarkable genes in ESCA, particularly those in the group of 51 connected genes, may be regulated by several drugs to affect the BP, CC or MF and were associated with those hub genes of ESCA, which, as a result, may influence ESCA pathogenesis.

In addition to the bioinformatics database analysis, drug repurposing was also investigated via structure exploration. Docking was used to screen the proteins and identify potential targets for a query ligand (69). Molecular docking is one of the key steps for proper computational reconstruction of actual ligand-receptor or protein-protein interactions, and thus is relevant to drug design and ligands discovery (70-74). In the present study, the binding affinity between drug molecules and proteins was determined. Apigenin, Prestwick-685 and menadione were predicted to be potential drugs that may affect the target genes, together with ESCA-associated hub genes that influence pathogenesis. Higher linking affinity in this step to hub genes in the network confirmed apigenin, Prestwick-685 and menadione to be significant drug candidates, as well as confirmed the CMAP results. Therefore, in taking full advantage of databases and molecule docking, drug repurposing of Prestwick-685 and menadione was achieved, as apigenin has been reported to induce apoptosis in ESCA cells (46). Thus, Prestwick-685 and menadione were considered to be significant novel drug candidates.

Furthermore, the biological significance of five vital hub genes, including STAT1, matrix MMP9, TIMP1, IL1B and IL8, for ESCA can be explained. According to previous studies (75), STAT1 was reported to be a tumor suppressor in ESCC by downregulating the activity of NF-κB and STAT3, and it was associated with the substantial downregulation of several pro-survival proteins such as B-cell lymphoma (Bcl)-2, Bcl-extra-large and survivin, as well as modulation of two G1 cell-cycle-regulatory proteins, p21waf1 and cyclin D1 (76). MMP9 was also demonstrated to be a prognostic factor in ESCA (77), and MMP9 upregulated by protein tyrosine kinase 7 through activation of activator protein 1 and NF-κB could increase the invasive properties of ESCC cells (78). Studies have identified that high serum levels of TIMP1 were associated with tumor progression and unfavorable prognosis in patients with ESCA (79,80). For IL1B, it was only reported that the rs16944 G>A polymorphism may contribute to ESCC susceptibility (81). For IL8, it is significantly upregulated during esophageal carcinogenesis, and the IL-8/CXC chemokine receptor 2 signaling pathway is a potential therapeutic target in EAC (82). To summarize, the significant biological functions of STAT1, MMP9, TIMP1, IL1B and IL8 in ESCA provided solid reasons for their being therapeutic targets for patients with ESCA, for which the novel drug candidates may serve certain positive functions in the molecular docking, as predicted.

The present study had certain limitations. The results relied heavily on the bioinformatics database and thus were significantly influenced by the refresh rate of data. Furthermore, drug experiments were not performed, meaning that the predicted drugs may lack effective verification. Despite the limitations, however, full use was made of the DEGs of ESCA in CMAP, STITCH, PPI network and molecular docking, as well as functional analysis including KEGG, PANTHER and GO analysis, to screen for novel drug candidates for ESCA and have confirmed their potential therapeutic effect at a bioinformatics level. Thus, to a certain extent, the present study may provide a reference for the chemotherapy of ESCA, in its molecular biology and methodology, which similar studies have not yet reported. Furthermore, the results require further investigation, as well as in vivo studies.

 Abbreviations ESCA

esophageal carcinoma

 DEG

differentially expressed genes

 TCGA

The Cancer Genome Atlas

 GTEx

Genotype‐Tissue Expression

 PPI

protein‐protein interaction

 CMAP

Connectivity Map

 KEGG

Kyoto Encyclopedia of Genes and Genomes

 GO

Gene Ontology

 BP

Biological Process

 CC

Cellular Component

 MF

Molecular Function

 STITCH

Search Tool for Interactions of Chemicals

 SMILES

Simplified Molecular‐Input Line‐Entry System

 Acknowledgments

The authors thank Dr Xia Yang (Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China), for providing valuable suggestions on writing the original manuscript.

 Funding

The present study was supported by the Project of Future Academic Star in Guangxi Medical University, China (grant no. WLXSZX18004) and the Guangxi Zhuang Autonomous Region University Student Innovative Plan, China (grant no. 2018049).

 Availability of data and materials

The datasets generated and analyzed during the current study are available in TCGA database (cancergenome.nih.gov), GTEx database (gtexportal.org/home) and CMAP database (portals.broadinstitute.org/cmap).

 Authors' contributions

The study was conceived and designed by YTC, JYX, QS and WJM. YTC, JYX and QS participated in the data mining. YTC analyzed and interpreted data and drafted the manuscript. JYX participated in drafting the manuscript. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References MaKCaoBGuoMThe detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinomaClin Epigenetics843201610.1186/s13148-016-0210-9271103004840959 SiegelRLMillerKDJemalACancer statistics, 2018CA Cancer J Clin68730201810.3322/caac.2144229313949 ErkizanHVJohnsonKGhimbovschiSKarkeraDTrachiotisGAdibHHoffmanEPWadleighRGAfrican-American esophageal squamous cell carcinoma expression profile reveals dysregulation of stress response and detox networksBMC Cancer17426201710.1186/s12885-017-3423-1286293675477112 JiangSZhangQSuYPanLNetwork-based differential analysis to identify molecular features of tumorigenesis for esophageal squamous carcinomaMolecules2323201810.3390/molecules23010088 YangXXMaMSangMXWangXXSongHLiuZKZhuSCRadiosensitization of esophageal carcinoma cells by knockdown of RNF2 expressionInt J Oncol4819851996201610.3892/ijo.2016.340426936624 MaZCaiHCuiYProgress in the treatment of esophageal neuroendocrine carcinomaTumour Biol391010428317711313201710.1177/101042831771131328653897 VellayappanBASoonYYKuGYLeongCNLuJJTeyJCChemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancerCochrane Database Syst Rev8CD010511201728829911 ChenGZZhuHCDaiWSZengXNLuoJHSunXCThe mechanisms of radioresistance in esophageal squamous cell carcinoma and current strategies in radiosensitivityJ Thorac Dis9849859201710.21037/jtd.2017.03.23284494965394057 Recio-BoilesABabikerHMCancer, EsophagealStatPearls [Internet]StatPearls PublishingTreasure Island, FL2018 SasakiYKatoKChemoradiotherapy for esophageal squamous cell cancerJpn J Clin Oncol46805810201610.1093/jjco/hyw08227380810 HaradaKMizrak KayaDBabaHAjaniJAImmune checkpoint blockade therapy for esophageal squamous cell carcinomaJ Thorac Dis10699702201810.21037/jtd.2018.01.120296071375864622 CaiZLvHCaoWZhouCLiuQLiHZhouFTargeting strategies of adenovirus mediated gene therapy and virotherapy for prostate cancer (Review)Mol Med Rep1664436458201710.3892/mmr.2017.7487289014905865813 GrishamRNIyerGLow-grade serous ovarian cancer: Current treatment paradigms and future directionsCurr Treat Options Oncol1954201810.1007/s11864-018-0571-830225651 Le GrazieMBiaginiMRTarocchiMPolvaniSGalliAChemotherapy for hepatocellular carcinoma: The present and the futureWorld J Hepatol9907920201710.4254/wjh.v9.i21.907288247425545136 MayankJaitakVDrug target strategies in breast cancer treatment: Recent developmentsAnticancer Agents Med Chem1414141427201410.2174/187152061466614040711485324712325 MichelsSWolfJStratified treatment in lung cancerOncol Res Treat39760766201610.1159/00045340627889787 JiaYXiaoZGongsunXXinZShangBChenGWangZJiangWCEP55 promotes the proliferation, migration and invasion of esophageal squamous cell carcinoma via the PI3K/Akt pathwayOncoTargets Ther1142214232201810.2147/OTT.S168861 NiyazMAbdurahmanATurghunAAwutICEP3 and CEP17 DNA probe potential in the genetic diagnosis and prognostic prediction of esophageal squamous cell cancerExp Ther Med1113751380201610.3892/etm.2016.3080270734524812153 WangHZhouYLiuQXuJMaYPrognostic value of SOX2, Cyclin D1, P53, and ki-67 in patients with esophageal squamous cell carcinomaOncoTargets Ther1151715181201810.2147/OTT.S160066 LinSLiuKZhangYJiangMLuRFoltsCJGaoXNobleMDZhaoTZhouZPharmacological targeting of p38 MAP-Kinase 6 (MAP2K6) inhibits the growth of esophageal adenocarcinomaCell Signal51222232201810.1016/j.cellsig.2018.08.00830102978 MacGregorTPCarterRGilliesRSFindlayJMKartsonakiCCastro-GinerFSahgalNWangLMChettyRMaynardNDTranslational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinomaSci Rep87265201810.1038/s41598-018-24232-2297399525940885 ChangZWJiaYXZhangWJSongLJGaoMLiMJZhaoRHLiJZhongYLSunQZLncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1J Exp Clin Cancer Res3756201810.1186/s13046-018-0724-4295300575848549 LiuBWangCChenPChengBChengYRACKI induces chemotherapy resistance in esophageal carcinoma by upregulating the PI3K/AKT pathway and Bcl-2 expressionOncoTargets Ther11211220201810.2147/OTT.S152818 YuXLiWXiaZXieLMaXLiangQLiuLWangJZhouXYangYTargeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosisBMC Cancer17449201710.1186/s12885-017-3442-y286591825490225 PangYLiuJLiXZhangYZhangBZhangJDuNXuCLiangRRenHNano Let 7b sensitization of eliminating esophageal cancer stem like cells is dependent on blockade of Wnt activation of symmetric divisionInt J Oncol5110771088201710.3892/ijo.2017.4104289023705592862 LambJCrawfordEDPeckDModellJWBlatICWrobelMJLernerJBrunetJPSubramanianARossKNThe Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and diseaseScience31319291935200610.1126/science.113293917008526 LinPXiongDDDangYWYangHHeYWenDYQinXGChenGThe anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: A comprehensive investigation based on high-throughput data and immunohistochemical validationOncotarget89249792521201710.18632/oncotarget.21438291909335696199 DangYWLinPLiuLMHeRQZhangLJPengZGLiXJChenGIn silico analysis of the potential mechanism of telocinobufagin on breast cancer MCF-7 cellsPathol Res Pract214631643201810.1016/j.prp.2018.03.02929656985 HeRQYangXLiangLChenGMaJMicroRNA-124-3p expression and its prospective functional pathways in hepatocellular carcinoma: A quantitative polymerase chain reaction, gene expression omnibus and bioinformatics studyOncol Lett15551755322018295521915840674 LiHMYangHWenDYLuoYHLiangCYPanDHMaWChenGHeYChenJQOverexpression of LncRNA HOTAIR is associated with poor prognosis in thyroid carcinoma: A study based on TCGA and GEO dataHorm Metab Res49388399201710.1055/s-0043-10334628351094 ShannonPMarkielAOzierOBaligaNSWangJTRamageDAminNSchwikowskiBIdekerTCytoscape: A software environment for integrated models of biomolecular interaction networksGenome Res1324982504200310.1101/gr.123930314597658403769 GaoLLiSHTianYXZhuQQChenGPangYYHuXHRole of downregulated miR-133a-3p expression in bladder cancer: A bioinformatics studyOncoTargets Ther1036673683201710.2147/OTT.S137433 HeRQWuPRXiangXLYangXLiangHWQiuXHYangLHPengZGChenGDownregulated miR-23b-3p expression acts as a predictor of hepatocellular carcinoma progression: A study based on public data and RT-qPCR verificationInt J Mol Med41281328312018294844295846654 LiangLWeiDMLiJJLuoDZChenGDangYWCaiXYPrognostic microRNAs and their potential molecular mechanism in pancreatic cancer: A study based on The Cancer Genome Atlas and bioinformatics investigationMol Med Rep1793995120185780175 PathanMKeerthikumarSAngCSGangodaLQuekCYWilliamsonNAMouradovDSieberOMSimpsonRJSalimAFunRich: An open access standalone functional enrichment and interaction network analysis toolProteomics1525972601201510.1002/pmic.20140051525921073 HsinKYGhoshSKitanoHCombining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacologyPLoS One8e83922201310.1371/journal.pone.0083922 HsinKYMatsuokaYAsaiYKamiyoshiKWatanabeTKawaokaYKitanoHsystemsDock: A web server for network pharmacology-based prediction and analysisNucleic Acids Res44W1W50713201610.1093/nar/gkw335271313844987901 WangJLiMWangYLiuXIntegrating subpathway analysis to identify candidate agents for hepatocellular carcinomaOncoTargets Ther912211230201610.2147/OTT.S97211 ZadorZKingATGeifmanNNew drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposingPLoS One13e0194701201810.1371/journal.pone.0194701295585155860760 LiuGHuXGaoLFengZPersonalized drug analysis in B cell chronic lymphocytic leukemia patientsMed Sci Monit2321592167201710.12659/MSM.900738284774395432060 NelsonNSzekeresKIclozanCRiveraIOMcGillAJohnsonGNwoguOGhansahTApigenin: Selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancerPLoS One12e0170197201710.1371/journal.pone.0170197 PalMKJaiswarSPDwivediAGoyalSDwivediVNPathakAKKumarVSankhwarPLRayRSSynergistic effect of graphene oxide coated nanotised apigenin with paclitaxel (GO-NA/PTX): A ROS dependent mitochondrial mediated apoptosis in ovarian cancerAnticancer Agents Med Chem1717211732201728443516 ShanSShiJYangPJiaBWuHZhangXLiZApigenin restrains colon cancer cell proliferation via targeted blocking of pyruvate kinase M2-dependent glycolysisJ Agric Food Chem6581368144201710.1021/acs.jafc.7b0275728829588 Vrhovac MadunićIMadunićJAntunovićMParadžikMGaraj-VrhovacVBreljakDMarijanovićIGajskiGApigenin, a dietary flavonoid, induces apoptosis, DNA damage, and oxidative stress in human breast cancer MCF-7 and MDA MB-231 cellsNaunyn Schmiedebergs Arch Pharmacol391537550201810.1007/s00210-018-1486-4 ZhouZTangMLiuYZhangZLuRLuJApigenin inhibits cell proliferation, migration, and invasion by targeting Akt in the A549 human lung cancer cell lineAnticancer Drugs28446456201710.1097/CAD.000000000000047928125432 ZhuHJinHPiJBaiHYangFWuCJiangJCaiJApigenin induced apoptosis in esophageal carcinoma cells by destruction membrane structuresScanning38322328201610.1002/sca.21273 YanXQiMLiPZhanYShaoHApigenin in cancer therapy: Anti-cancer effects and mechanisms of actionCell Biosci750201710.1186/s13578-017-0179-x290340715629766 SungBChungHYKimNDRole of apigenin in cancer prevention via the induction of apoptosis and autophagyJ Cancer Prev21216226201610.15430/JCP.2016.21.4.216 Pérez-ArredondoACázares-RamírezECarrillo-MoraPMartínez-VargasMCárdenas-RodríguezNCoballase-UrrutiaEAlemón-MedinaRSampieriAIIINavarroLCarmona-AparicioLBaclofen in the therapeutic of sequele of traumatic brain injury: SpasticityClin Neuropharmacol39311319201610.1097/WNF.0000000000000179275637455106081 ErtzgaardPCampoCCalabreseAEfficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofenJ Rehabil Med49193203201710.2340/16501977-221128233010 SharmaVDeALamoriaSLambaBMBaclofen-responsive hiccups after esophageal stenting for malignancy-related dysphagiaProc Bayl Univ Med Cent29150201610.1080/08998280.2016.11929394270345494790551 YomiyaKMatsuoNTomiyasuSYoshimotoTTamakiTSuzukiTMatobaMBaclofen as an adjuvant analgesic for cancer painAm J Hosp Palliat Care26112118200910.1177/1049909108327968 KovalAVVlasovPShichkovaPKhunderyakovaSMarkovYPanchenkoJVolodinaAKondrashovFAKatanaevVLAnti-leprosy drug clofazimine inhibits growth of triple-negative breast cancer cells via inhibition of canonical Wnt signalingBiochem Pharmacol87571578201410.1016/j.bcp.2013.12.007 DurusuIZHüsnügilHHAtaşHBiberAGerekçiSGüleçEAÖzenCAnti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell lineLeuk Res553340201710.1016/j.leukres.2017.01.01928122281 LeeMHChoYKimDHWooHJYangJYKwonHJYeonMJParkMKimSHMoonCMenadione induces G2/M arrest in gastric cancer cells by downregulation of CDC25C and proteasome mediated degradation of CDK1 and cyclin B1Am J Transl Res8524652552016 PrasadCVNayakVLRamakrishnaSMallavadhaniUVNovel menadione hybrids: Synthesis, anticancer activity, and cell-based studiesChem Biol Drug Des91220233201810.1111/cbdd.13073 DelwarZMSidenACruzMHYakisichJSMenadione : Sodium orthovanadate combination eliminates and inhibits migration of detached cancer cellsISRN Pharmacol20123071022012 YamadaAOsadaSTanahashiTMatsuiSSasakiYTanakaYOkumuraNMatsuhashiNTakahashiTYamaguchiKNovel therapy for locally advanced triple-negative breast cancerInt J Oncol4712661272201510.3892/ijo.2015.3113262528424583525 TeixeiraJAmorimRSantosKSoaresPDattaSCortopassiGASerafimTLSardãoVAGarridoJBorgesFDisruption of mitochondrial function as mechanism for anti-cancer activity of a novel mitochondriotropic menadione derivativeToxicology393123139201810.1016/j.tox.2017.11.014 WróbelAMGregoraszczukELAction of methyl-, propyl- and butylparaben on GPR30 gene and protein expression, cAMP levels and activation of ERK1/2 and PI3K/Akt signaling pathways in MCF-7 breast cancer cells and MCF-10A non-transformed breast epithelial cellsToxicol Lett238110116201510.1016/j.toxlet.2015.08.00126253279 LeiterLAShestakovaMVSatmanIEffectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: Analyses from the EASYDia trialDiabetol Metab Syndr1030201810.1186/s13098-018-0331-8 MikovMDanicMPavlovicNStanimirovBGoločorbin-KonSStankovKAl-SalamiHPotential applications of gliclazide in treating type 1 diabetes mellitus: Formulation with bile acids and probioticsEur J Drug Metab Pharmacokinet43269280201810.1007/s13318-017-0441-y SliwinskaARogalskaASzwedMKasznickiJJozwiakZDrzewoskiJGliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cellsMol Biol Rep3952535267201210.1007/s11033-011-1323-z3310990 SliwinskaASliwinskiTKasznickiJDrzewoskiJEffect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cellsJ Physiol Pharmacol61347353201020610866 CaponigroFDi GennaroEIonnaFLongoFAversaCPavoneEMaglioneMGDi MarzoMMutoPCavalcantiEPhase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trialBMC Cancer16918201610.1186/s12885-016-2957-y278841405123351 ScialdoneAHasniMSDammJKLennartssonAGullbergUDrottKThe HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivoOncotarget83740937422201710.18632/oncotarget.16964284451585514918 ShaSZhaiYLinCWangHChangQSongSRenMLiuGA combination of valproic acid sodium salt, CHIR99021, E-616452, tranylcypromine, and 3-Deazaneplanocin A causes stem cell-like characteristics in cancer cellsOncotarget85330253312201710.18632/oncotarget.18396288818125581111 WeiMMaoSLuGLiLLanXHuangZChenYZhaoMZhaoYXiaQValproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversalBMC Cancer18434201810.1186/s12885-018-4344-3296657875902941 XuXHuangMZouXDocking-based inverse virtual screening: Methods, applications, and challengesBiophys Rep4116201810.1007/s41048-017-0045-8295770655860130 AbdolmalekiAGhasemiJBGhasemiFComputer aided drug design for multi-target drug design: SAR/QSAR, molecular docking and pharmacophore methodsCurr Drug Targets18556575201710.2174/1389450117666160101120822 BartuziDKaczorAATargowska-DudaKMMatosiukDRecent advances and applications of molecular docking to G protein-coupled receptorsMolecules2222201710.3390/molecules22020340 de RuyckJBrysbaertGBlosseyRLensinkMFMolecular docking as a popular tool in drug design, an in silico travelAdv Appl Bioinform Chem91112016273905304930227 RosanoCPonassiMSantollaMFPisanoAFelliLVivacquaAMaggioliniMLappanoRMacromolecular modelling and docking simulations for the discovery of selective GPER ligandsAAPS J184146201610.1208/s12248-015-9844-34706286 ScottiLMendonca JuniorFJIshikiHMRibeiroFFSinglaRKBarbosa FilhoJMDa SilvaMSScottiMTDocking studies for multi-target drugsCurr Drug Targets18592604201710.2174/1389450116666150825111818 ZhangYMolaviOSuMLaiRThe clinical and biological significance of STAT1 in esophageal squamous cell carcinomaBMC Cancer14791201410.1186/1471-2407-14-791253551394233059 ZhangYZhangYYunHLaiRSuMCorrelation of STAT1 with apoptosis and cell-cycle markers in esophageal squamous cell carcinomaPLoS One9e113928201410.1371/journal.pone.0113928254381564250046 Klimczak-BitnerAAKordekRBitnerJMusiałJSzemrajJExpression of MMP9, SERPINE1 and miR-134 as prognostic factors in esophageal cancerOncol Lett1241334138201610.3892/ol.2016.5211278957825104243 ShinWSHongYLeeHWLeeSTCatalytically defective receptor protein tyrosine kinase PTK7 enhances invasive phenotype by inducing MMP-9 through activation of AP-1 and NF-κB in esophageal squamous cell carcinoma cellsOncotarget77324273256201610.18632/oncotarget.12303276893255341976 JuchniewiczAKowalczukOMilewskiRLaudańskiWDzięgielewskiPKozłowskiMNiklińskiJMMP-10, MMP-7, TIMP-1 and TIMP-2 mRNA expression in esophageal cancerActa Biochim Pol64295299201710.18388/abp.2016_140828510611 KozłowskiMLaudańskiWMroczkoBSzmitkowskiMMilewskiRŁapućGSerum tissue inhibitor of metallo-proteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patientsAdv Med Sci58227234201310.2478/ams-2013-0017 ZhengLYinJWangLWangXShiYShaoATangWDingGLiuCChenSInterleukin 1B rs16944 G>A polymorphism was associated with a decreased risk of esophageal cancer in a Chinese populationClin Biochem4614691473201310.1016/j.clinbiochem.2013.05.05023726808 ShrivastavaMSHussainZGiriczOShenoyNPolineniRMaitraAVermaATargeting chemokine pathways in esophageal adenocarcinomaCell Cycle1333203327201410.4161/15384101.2014.968426254855764614313

Volcano plot of differentially expressed genes between esophageal carcinoma and normal tissues.

GO analysis of the differentially expressed genes of ESCA (|log2 fold-change| ≥2). Red bars, Biological Process; blue bars, Cellular Component; green bars, Molecular Function. GO, Gene Ontology; ESCA, esophageal carcinoma.

Protein-protein interaction network of differentially expressed genes of esophageal carcinoma based on Search Tool for the Retrieval of Interacting Genes. The network is presented with an attribute circle layout. Blue lines indicate edges between nodes; yellow circles indicate hub gene nodes (ELN, TIMP1, ICAM1, TOP2A, IL1B, COL1A1, IL8, MMP9, SPP1, STAT1 and CXCL10); gray circles indicate other nodes. Hub genes were extracted with all degrees ≥30.

Target genes of 9 second screening drugs based on Search Tool for Interactions of Chemicals. (A) Apigenin; (B) Prestwick-685 (clofazimine); (C) menadione; (D) baclofen; (E) dequalinium chloride (dequalinium); (F) butyl hydroxybenzoate (butylparaben); (G) acetazolamide; (H) gliclazide; (I) valproic acid (valproate).

Intersection of 827 DEGs of ESCA and 70 target genes of 9 second screening drugs. DEG, differentially expressed gene; ESCA, esophageal carcinoma.

Protein-protein interaction network of ESCA-associated hub genes and drug-associated target genes based on STRING. All the 51 connected nodes were confirmed by Experiments and Databases of STRING. Unassociated nodes are hidden. The green circle represents target genes of predicted drug candidates, whereas the yellow circle represents the hub genes of ESCA. ESCA, esophageal carcinoma; STRING, Search Tool for the Retrieval of Interacting Genes.

Network of drug candidates-target genes-ESCA-associated hub genes. Red oblongs represent predicted drug candidates; yellow circles represents 44/51 selected genes, which were also target genes of goal drugs; blue polygons represent the other 7 genes also belonging to ESCA-associated hub genes. ESCA, esophageal carcinoma.

GO analysis of 51 genes, including 44 potential drug-associated target genes and 7 ESCA-associated hub genes. Red bars, Biological Process; blue bars, Cellular Component; green bars, Molecular Function. GO, Gene Ontology; ESCA, esophageal carcinoma.

Three-dimensional structures of the significant test ligand (residue)-protein based on systemDock. (A) Apigenin-STAT1; (B) apigenin-tissue inhibitor of metalloproteinase 1; (C) apigenin-MMP9; (D) Prestwick-685-STAT1; (E) Prestwick-685-MMP9; (F) Prestwick-685-IL-1B; (G) menadione-STAT1; (H) menadione-MMP9; (I) menadione-IL-1B. STAT1, signal transducer and activator of transcription 1; MMP9, matrix metalloproteinase 9; IL-1B, interleukin 1B.

Two-dimensional structures of the significant test ligand (residue)-protein based on systemDock. (A) Apigenin-STAT1; (B) apigenin-tissue inhibitor of metalloproteinase 1; (C) apigenin-MMP9; (D) Prestwick-685-STAT1; (E) Prestwick-685-MMP9; (F) Prestwick-685-IL-1B; (G) menadione-STAT1; (H) menadione-MMP9; (I) menadione-IL-1B. STAT1, signal transducer and activator of transcription 1; MMP9, matrix metalloproteinase 9; IL-1B, interleukin 1B.

Flow chart of the methodology used. The blue boxes represent the process, the green boxes represent the screening drugs, and the yellow boxes represent the other results for corresponding processes. The red dotted line indicates the drug screening process.

Two-time Kyoto Encyclopedia of Genes and Genomes analysis.

Group Gene set Description P-value FDR Overlapping genes
A hsa04974 Protein digestion and absorption 2.45×10−7 7.41×10−5 10008, 10136, 1277, 1278, 1281, 1282, 1284, 1289, 1300, 2006, 477, 5644, 5645, 643834, 643847
hsa04512 ECM-receptor interaction 1.61×10−5 2.44×10−3 1277, 1278, 1282, 1284, 3655, 3679, 3685, 3691, 375790, 3918, 6696, 7148
hsa04610 Complement and coagulation cascades 5.86×10−5 5.92×10−3 1675, 2149, 2151, 5054, 5055, 5265, 5328, 5329, 713, 714, 730
hsa05146 Amebiasis 1.20×10−4 9.06×10−3 1277, 1278, 1281, 1282, 1284, 2919, 3553, 3576, 3918, 5275, 6317, 6318
hsa00590 Arachidonic acid metabolism 2.01×10−4 1.22×10−2 100137049, 1571, 239, 247, 2878, 50487, 5320, 5730, 874
hsa00982 Drug metabolism: Cytochrome P450 5.09×10−4 2.04×10−2 125, 131, 1571, 218, 222, 2327, 2946, 316, 54577
hsa04062 Chemokine signaling pathway 5.22×10−4 2.04×10−2 10563, 2919, 2921, 3576, 3579, 3627, 4067, 4283, 6358, 6362, 6363, 6364, 6366, 6373, 6772, 9560
hsa04933 AGE-RAGE signaling pathway in diabetic complications 5.38×10−4 2.04×10−2 1277, 1278, 1281, 1282, 1284, 3383, 3553, 3576, 5054, 5292, 6772
hsa00980 Metabolism of xenobiotics by cytochrome P450 7.70×10−4 2.59×10−2 125, 131, 1571, 218, 222, 2946, 29785, 54577, 874
hsa04060 Cytokine-cytokine receptor interaction 1.42×10−3 4.30×10−2 10563, 2919, 2921, 3553, 3576, 3579, 3624, 3627, 4233, 4283, 51330, 53833, 6358,6362, 6363, 6364, 6366, 6373, 9560
B hsa00982 Drug metabolism: Cytochrome P450 3.84×10−7 1.16×10−4 1548, 1555, 1559, 316, 4128, 4129, 54658
hsa05210 Colorectal cancer 3.41×10−6 4.02×10−4 207, 2353, 2932, 54205, 7157, 836
hsa04915 Estrogen signaling pathway 4.40×10−6 4.02×10−4 207, 2099, 2353, 2550, 3763, 4318, 9568
hsa05161 Hepatitis B 5.40×10−6 4.02×10−4 207, 2185, 2353, 4318, 54205, 6772, 7157, 836
hsa00380 Tryptophan metabolism 6.63×10−6 4.02×10−4 1545, 316, 4128, 4129, 847
hsa04668 TNF signaling pathway 8.30×10−6 4.19×10−4 207, 2353, 3553, 3627, 4318, 5743, 836
hsa05014 Amyotrophic lateral sclerosis 2.24×10−5 9.68×10−4 54205, 598, 7157, 836, 847
hsa04210 Apoptosis 4.01×10−5 1.52×10−3 142, 207, 2353, 54205, 598, 7157, 836
hsa00590 Arachidonic acid metabolism 5.82×10−5 1.96×10−3 1555, 1559, 5319, 5320, 5743
hsa00830 Retinol metabolism 7.32×10−5 2.07×10−3 1548, 1555, 1559, 316, 54658

Group A contains the differentially expressed genes of ESCA (|log2 fold-change| ≥2); Group B contains 51 genes including 44 drug candidate-associated target genes and 7 ESCA-associated hub genes. ESCA, esophageal carcinoma; FDR, false discovery rate; ECM, extracellular matrix; AGE, advanced glycation end-products; RAGE, receptor for AGE; TNF, tumor necrosis factor.

Two-time Protein Annotation Through Evolutionary Relationships analysis.

Group Gene set Description P-value FDR Overlapping genes
A P00050 Plasminogen-activating cascade 2.39×10−7 2.70×10−5 5328, 4312, 5055, 5054, 4314, 4318, 5329
P00011 Blood coagulation 1.64×10−3 9.25×10−2 5328, 5265, 5055, 5054, 2149, 5329
P00034 Integrin signaling pathway 3.46×10−3 1.30×10−1 10095, 1277, 1281, 1282, 3685, 1278, 1284, 3691, 1289, 3655, 1300, 3679, 3918
P06959 CCKR signaling map 1.55×10−2 4.39×10−1 5328, 7031, 5055, 5054, 3685, 4067, 4314, 4316, 2919, 3576, 4953, 4318
P00031 Inflammation mediated by chemokine and cytokine signaling pathway 1.94×10−2 4.39×10−1 6366, 10095, 3627, 3576, 239, 3579, 4629, 6362, 72, 6364, 3710, 4776, 9560
B P06959 CCKR signaling map 1.00×10−5 1.14×10−3 2353, 2641, 4318, 6869, 207, 5743, 836, 2932, 598, 2185
P00006 Apoptosis signaling pathway 1.05×10−3 5.93×10−2 2353, 7157, 207, 836, 54205, 598
P00029 Huntington disease 1.27×10−2 3.88×10−1 2353, 7157, 627, 207, 836
P00036 Interleukin signaling pathway 1.62×10−2 3.88×10−1 2353, 207, 6772, 2932
P04372 5-Hydroxytryptamine degradation 1.71×10−2 3.88×10−1 4128, 4129
P04397 p53 pathway by glucose deprivation 2.30×10−2 4.34×10−1 7157, 207
P00001 Adrenaline and noradrenaline biosynthesis 3.69×10−2 4.78×10−1 4128, 4129
P04393 Ras pathway 4.36×10−2 4.78×10−1 207, 6772, 2932
P00020 Fas signaling pathway 4.76×10−2 4.78×10−1 142, 836

Group A contains the differentially expressed genes of ESCA (|log2 fold-change| ≥2); Group B contains 51 genes including 44 drug candidate-associated target genes and 7 ESCA-associated hub genes. ESCA, esophageal carcinoma; FDR, false discovery rate; CCKR, chole-cystokinin receptor.

First screening drugs extracted from CMAP (scores <-0.85).

No. CMAP name Score STITCH Canonical SMILES
6817 Verteporfin −1 Verteporfin CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C) CCC(=O)OC)C(=C3C)CCC(=O)O)C=C
4578 Apigenin −0.964 Apigenin C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)OC4C(C(C(C(O4)CO)O)O)O)O)O
4567 Cefixime −0.912 Cefixime C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OCC(=O)O)/C3=CSC(=N3)N)SC1)C(=O)O
7382 Prestwick-685 −0.901 Clofazimine CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl
4662 Menadione −0.896 Menadione CC1=CC(=O)C2=CC=CC=C2C1=O
6313 Baclofen −0.889 Baclofen C1=CC(=CC=C1C(CC(=O)O)CN)Cl
6296 Dequalinium chloride −0.883 Dequalinium CC1=[N+](C2=CC=CC=C2C(=C1)N)CCCCCCCCCC[N+]3=C(C=C(C4=CC=CC=C43)N)C.[Cl−].[Cl−]
4647 Butyl hydroxybenzoate −0.882 Butylparaben CCCCOC(=O)C1=CC=C(C=C1)O
4645 Naloxone −0.876 Naloxone C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O
3556 Verteporfin −0.868 Verteporfin CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C) CCC(=O)OC)C(=C3C)CCC(=O)O)C=C
4556 Paroxetine −0.865 Paroxetine C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
1850 Acetazolamide −0.863 Acetazolamide CC(=O)NC1=NN=C(S1)S(=O)(=O)N
5089 Gliclazide −0.86 Gliclazide CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2
1155 Valproic acid −0.859 Valproate CCCC(CCC)C(=O)O
2901 Metacycline −0.855 Methacycline CN(C)C1C2C(C3C(=C)C4=C(C(=CC=C4)O)C(=C3C(=O)C2(C(=O)C(=C1O)C(=O)N)O)O)O.Cl

CMAP, Connectivity Map; STITCH, Search Tool for Interactions of Chemicals; SMILES, Simplified Molecular-Input Line-Entry System.

Predicted binding affinity between drug candidates and hub genes.

Gene PDB identifier Test compound Docking score (pKd/pKi)
STAT1 1BF5 580043: Apigenin 7.866
STAT1 1BF5 2794: Prestwick-685 7.738
MMP9 1ITV 2794: Prestwick-685 6.768
TIMP1 3MA2 580043: Apigenin 6.593
MMP9 1ITV 580043: Apigenin 6.439
IL1B 2NVH 580043: Apigenin 6.422
STAT1 1BF5 4055: Menadione 6.403
MMP9 1ITV 4055: Menadione 5.612
IL1B 2NVH 4055: Menadione 5.592
IL8 1QE6 4055: Menadione 5.431
IL1B 2NVH 2794: Prestwick-685 5.417
TIMP1 3MA2 4055: Menadione 5.191
IL8 1QE6 580043: Apigenin 5.075
IL8 1QE6 2794: Prestwick-685 4.687
IL8 1QE6 3475: Gliclazide 4.617
TIMP1 3MA2 3475: Gliclazide 4.385
TIMP1 3MA2 3121: Valproic acid 4.344
STAT1 1BF5 3121: Valproic acid 4.23
MMP9 1ITV 3121: Valproic acid 4.131
IL1B 2NVH 3121: Valproic acid 4.092
IL8 1QE6 3121: Valproic acid 4.06
TIMP1 3MA2 2794: Prestwick-685 3.802
TIMP1 3MA2 7184: Butyl hydroxybenzoate 3.73
IL8 1QE6 7184: Butyl hydroxybenzoate 3.352
IL1B 2NVH 7184: Butyl hydroxybenzoate 3.148
STAT1 1BF5 7184: Butyl hydroxybenzoate 3.095
IL8 1QE6 2284: Baclofen 2.957
IL1B 2NVH 3475: Gliclazide 2.894
MMP9 1ITV 3475: Gliclazide 2.871
MMP9 1ITV 7184: Butyl hydroxybenzoate 2.742
TIMP1 3MA2 2284: Baclofen 2.734
STAT1 1BF5 3475: Gliclazide 2.695
MMP9 1ITV 2284: Baclofen 2.571
IL1B 2NVH 2284: Baclofen 2.568
STAT1 1BF5 2284: Baclofen 2.371

PDB, Protein Data Bank.